Something for everyone at next Thursday's Proactive Investors One2One Forum in London: ImmuPharma, Oxford Pharmascience, Seeing Machines and Probability

Exciting barely covers it. We have a line-up that offers something for everyone at the Proactive Investors One2One Forum in London next Thursday (February 9). We have ImmuPharma and Oxford Pharmascience presenting alongside Seeing Machines and Probability.

Each has attracted an incredible amount of interest. So if you haven’t signed up already, you really need to do so soon to avoid disappointment. Please click here to register for the event.

All the hard work is starting to pay off for mobile gambling specialist Probability (LON:PBTY), which is at the inflection point.

The latest results showed that sales are starting to take off, while the business came close to break-even despite significant increases in marketing spend, particularly on TV.

A recent report by the City broker Numis suggested Probability would be a logical partner for Facebook as the social media giant seeks to boost its mobile revenues.

Joining us to talk about this and all the other developments at Probability will be chief executive Charles Cohen.

Seeing Machines (LON:SEE) is an expert in the cutting edge arena of facial recognition.

The technology is being used in a fatigue monitor for drivers, and is also an integral part of the world’s first 3D laptop.

However this is a fraction of its potential as Ken Kroeger will reveal when he joins us at the Chesterfield Mayfair Hotel.

“There are so many uses for this technology,” he said in a recent interview.

“We are talking to all the big players in the handheld device space. There are some technical challenges there moving it to low output devices, but be if we can get there it will be big.

“If you can move it into an area where you are selling tens or twenty million devices – even at a fraction of dollar a time you are still talking a lot of money.”

Oxford Pharmascience (LON:OXP) is developing smart technology that could save its larger and more illustrious brethren millions a year in lost sales.

Its suite of products allows medicines to be taken in various ways, which has the potential to create product extension for some the big over-the-counter and prescription drugs.

“The model is changing for the big pharma companies,” said chief executive Nigel Theobald. He will be with us next Thursday to explain more.

Very rarely does a small drug company have the opportunity to do the same transaction twice – with every prospect of getting an even better deal the second time around.

This is exactly what has happened with ImmuPharma (LON:IMM) and its leading drug Lupuzor, which is expected to attract the attention of the drug sector’s big boys.

“We expect Immupharma not only to re-licence Lupuzor sooner than the market anticipates (and this time with a big pharma company) but also that the up-front payment will be of a quantum that results in its enterprise value falling near to, or even below, zero,” said Navid Malik, analysts at Merchant Securities.

Bringing us up to date with events will be Dimitri Dimitriou.

Our investor forums are completely free to attend. Each company has approximately 30 minutes to give a short presentation and for Q&A. Please join us at 5:40pm to get yourself a seat and to allow for a prompt 6:00pm start.

Following the presentations there will be a complimentary bar and an assortment of the finest hot & cold canapes, giving you the opportunity to speak with the directors and other investors.